How Analysts Rated Evolent Health, Inc. (NYSE:EVH) Last Week?

June 15, 2018 - By Maria Brooks

Evolent Health, Inc. (NYSE:EVH) Logo

Evolent Health, Inc. (NYSE:EVH) Ratings Coverage

Among 11 analysts covering Evolent Health (NYSE:EVH), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Evolent Health had 14 analyst reports since January 2, 2018 according to SRatingsIntel. The stock of Evolent Health, Inc. (NYSE:EVH) has “Buy” rating given on Tuesday, January 2 by Cantor Fitzgerald. SunTrust maintained Evolent Health, Inc. (NYSE:EVH) on Thursday, June 7 with “Buy” rating. Wells Fargo maintained the stock with “Outperform” rating in Wednesday, February 28 report. KeyBanc Capital Markets maintained it with “Overweight” rating and $26 target in Thursday, June 7 report. Robert W. Baird maintained the shares of EVH in report on Thursday, January 11 with “Buy” rating. The firm has “Buy” rating given on Wednesday, January 10 by KeyBanc Capital Markets. The company was downgraded on Tuesday, April 24 by J.P. Morgan. The stock has “Buy” rating by Piper Jaffray on Monday, June 4. The firm earned “Buy” rating on Tuesday, February 13 by Jefferies. As per Tuesday, April 24, the company rating was reinitiated by JP Morgan. Below is a list of Evolent Health, Inc. (NYSE:EVH) latest ratings and price target changes.

07/06/2018 Broker: SunTrust Rating: Buy New Target: $30.0000 Maintain
07/06/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $24 New Target: $26 Maintain
04/06/2018 Broker: PiperJaffray Rating: Overweight New Target: $30 Initiates Coverage On
04/06/2018 Broker: Piper Jaffray Rating: Buy New Target: $30.0000 Initiate
30/05/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $24 Maintain
14/05/2018 Broker: Robert W. Baird Rating: Buy New Target: $25.0000 Maintain
24/04/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Reinitiate
24/04/2018 Broker: J.P. Morgan Rating: Hold New Target: $17.0000 Downgrade
28/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $24 Maintain
28/02/2018 Broker: Wells Fargo Rating: Outperform Old Target: $27 New Target: $20 Maintain

The stock decreased 0.43% or $0.1 during the last trading session, reaching $22.95. About 326,362 shares traded. Evolent Health, Inc. (NYSE:EVH) has declined 16.53% since June 15, 2017 and is downtrending. It has underperformed by 29.10% the S&P500.

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company has market cap of $1.79 billion. It operates as a managed services firm that supports integrated health systems in migration toward value care and population health management. It currently has negative earnings. The companyÂ’s services include providing clients with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services.

More news for Evolent Health, Inc. (NYSE:EVH) were recently published by: Globenewswire.com, which released: “Report: Developing Opportunities within RealNetworks, Acacia Communications, Medical Transcription Billing, Evolent …” on June 11, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on June 04, 2018 is yet another important article.

Evolent Health, Inc. (NYSE:EVH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: